文献速递胸部肿瘤放疗

实性成分占比对≤3cm肺癌放疗预后的影响

Impact of Consolidation-to-Tumor Ratio on Prognosis After Radiation therapy for Lung Cancer With a Lesion Diameter of 3 cm or Less.
PubMed 文献 · Adv Radiat Oncol · 2026-06-21

本研究纳入265例≤3cm无淋巴结及远处转移的NSCLC患者,2015–2022年接受根治性放疗,按实性成分占比(CTR)分为GGO为主、实性为主和纯实性三组。纯实性组3年总生存(79.0% vs 96.5%)和无进展生存(64.5% vs 93.1%)显著差于含GGO组,CTR模型预后预测优于T分期模型。

要点

  • 纯实性组3年OS 79.0%、PFS 64.5%,显著差于含GGO组的96.5%和93.1%。
  • GGO为主组未观察到复发或死亡。
  • CTR模型AIC更低(895.6 vs 907.4)、C指数更高(0.69 vs 0.67),优于T分期模型。

核心结论

  • CTR是早期NSCLC根治性放疗的稳健预后指标,优于传统T分期。
  • 将CTR纳入临床决策可能比单纯肿瘤大小提供更准确的风险分层。

研究设计与样本

  • 回顾性纳入2015–2022年接受单纯根治性放疗、病灶直径≤3cm且无淋巴结或远处转移的NSCLC患者265例。
  • 按CTR分为GGO为主(≤0.5,25例)、实性为主(>0.5至<1.0,39例)和纯实性(1.0,201例)三组。
  • 采用Akaike信息准则和一致性指数比较CTR模型与T分期模型对无进展生存的预后预测性能。

主要发现

  • 中位随访50.2个月,GGO为主组未观察到复发或死亡。
  • 纯实性组3年总生存率79.0%,含GGO组(GGO为主+实性为主)为96.5%。
  • 纯实性组3年无进展生存率64.5%,含GGO组为93.1%,且纯实性组远处转移率更高。
  • 多因素分析中CTR模型AIC为895.6、C指数0.69,T分期模型AIC为907.4、C指数0.67。

关键数值与推荐

  • CTR分组界值:GGO为主≤0.5,实性为主>0.5至<1.0,纯实性=1.0。
  • CTR模型较T分期模型AIC更低(895.6 vs 907.4)、C指数更高(0.69 vs 0.67)。

临床怎么用

  • 对≤3cm早期NSCLC拟行根治性放疗者,可依据CTR进行风险分层,纯实性病变更需关注远处转移风险。
  • CTR可作为优于单纯T分期的预后判断工具纳入临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Accurate risk stratification is essential for optimizing radiation therapy for early stage non-small cell lung cancer (NSCLC). This study evaluated whether the consolidation-to-tumor ratio (CTR) or conventional clinical T stage provides superior prognostic value for patients treated with definitive radiation therapy. METHODS AND MATERIALS: This study included patients with NSCLC with a lesion diameter ≤3 cm, without lymph node or distant metastases, who underwent definitive radiation therapy alone between 2015 and 2022. Patients were categorized into 3 CTR groups: ground-glass opacity (GGO)-dominant (≤0.5), solid-dominant (>0.5 to <1.0), and pure-solid (1.0). Prognostic performance for progression-free survival was compared between CTR-based and T-stage-based models using the Akaike Information Criterion and Concordance Index. RESULTS: In total, 265 patients (25 GGO-dominant, 39 solid-dominant, and 201 pure-solid) were analyzed. The median follow-up was 50.2 months. No recurrences or deaths were observed in the GGO-dominant group. The pure-solid group exhibited significantly poorer 3-year outcomes than the containing-GGO group (GGO-dominant + solid-dominant) for overall survival (79.0% vs 96.5%) and progression-free survival (64.5% vs 93.1%), with higher rates of distant metastasis. In multivariate analysis, the CTR-based model demonstrated a lower Akaike Information Criterion (895.6 vs 907.4) and a higher Concordance Index (0.69 vs 0.67) than the T-stage-based model, indicating better goodness-of-fit and predictive ability. CONCLUSIONS: CTR is a robust prognostic indicator, superior to T-stage, in early stage NSCLC treated with radiation therapy. Incorporating CTR into clinical decision-making may provide more accurate risk stratification than tumor size alone.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Nakamura M, Hirata H, Hiroshima Y, et al. Impact of Consolidation-to-Tumor Ratio on Prognosis After Radiation therapy for Lung Cancer With a Lesion Diameter of 3 cm or Less. Adv Radiat Oncol. 2026. PMID: 42519672. doi:10.1016/j.adro.2026.102122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。